Regeneron Pharmaceuticals (NASDAQ: REGN) announced the U.S. Food and Drug Administration has accepted its Biologics License Application for garetosmab under ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE